Pfizer maintained sales forecasts for its COVID-19 products on Tuesday after a series of hikes to the sales outlook for its COVID-19 vaccine last year, in a sign that dizzying growth has slowed.
The company said it expects US$22 billion in sales of its COVID-19 pill Paxlovid this year, compared with analysts' average expectation of $26.1 billion. In prepared remarks for the company's conference call with investors, Chief Executive Albert Bourla said the company had seen a significant pickup in the drug's use in the United States recently, and that some countries experiencing recent outbreaks had asked for more treatment courses.
Pfizer expects to submit data supporting authorisation of a three-dose regimen of the vaccine for children under the age of five to US regulators by early June. The US Food and Drug Administration has already scheduled meetings later in June to consider authorisation in that age group.
Being cancer-stricken and begging CPF Board to repay overdue debt; that which in any case cannot be done as the money had been commingled and funneled to private entity Temasek Holdings for Ho Ching to wager on unviable, untenable and ultimately, invariably doomed gambles
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.